Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reproteβ
- Development stage
- Unknown
- Lead developer
- Pharma Foods International
- Modality
- Peptides
01
Overview
Reproteβ is a bio-active peptide therapeutic candidate developed by Pharma Foods International for the treatment of bone diseases. It is derived from the company's proprietary research into egg-based bioactive substances, specifically focusing on peptides that influence bone metabolism. The drug is intended to regulate bone health, potentially by promoting bone formation or reducing bone resorption, although its specific molecular target has not been publicly disclosed. It is currently in the early stages of clinical development, transitioning from preclinical studies to Phase 1 trials.
- Brand names
- Reproteβ
- Other names
- Reprotebeta
Beyond the preview
Go deeper on Reproteβ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reproteβ.